Listed

Maravai Lifesciences Holdings, Inc.: Form 10-Q for the period ended Jun 30, 2024

Filed with the SEC on Aug 8, 2024 and accepted by EDGAR at Aug 8, 2024, 16:06 ET.

Share

Management's discussion and analysis

As filed, 66,614 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

You should read the following discussion and analysis of financial condition and results of operations together with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission. This discussion and analysis reflects our historical results of operations and financial position and contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed in or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023. Please also see the section titled “Special Note Regarding Forward-Looking Statements.” We were incorporated in August 2020 and, pursuant to the Organizational Transactions described in Note 1 to our condensed consolidated financial statements, became a holding company whose principal asset is a controlling equity interest in Topco LLC. As the sole managing member of Topco LLC, we operate and control the business and affairs of Topco LLC and its subsidiaries. Accordingly, we consolidate Topco LLC in our consolidated financial statements and report a non-controlling interest related to the portion of Topco LLC not owned by us. Because the Organizational Transactions were considered transactions between entities under common control, the consolidated financial statements for periods prior to the Organizational Transactions and the initial public offering have been adjusted to combine the previously separate entities for presentation purposes. Unless otherwise noted or the context otherwise requires, references in this Quarterly Report on Form 10-Q to “we,” “us” or “our” refer to Maravai LifeSciences Holdings, Inc. and its subsidiaries.

Overview

We are a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. Our customers include the top global biopharmaceutical companies ranked by research and development expenditures according to industry consultants, and many other emerging biopharmaceutical and life sciences research companies, as well as leading academic research institutions and in vitro diagnostics companies. Our products address the key phases of biopharmaceutical development and include complex nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

We have and will continue to build a transformative life sciences products company by acquiring businesses and accelerating their growth through capital infusions and industry expertise. Biomedical innovation is dependent on a reliable supply of reagents in the fields of nucleic acid production, biologics safety testing and protein labeling. From inventive startups to the world’s leading biopharmaceutical, vaccine, diagnostics and gene and cell therapy companies, these customers turn to us to solve their complex discovery challenges and help them streamline and scale their supply chain needs beginning from research and development through clinical trials to commercialization.

Our primary customers are biopharmaceutical companies who are pursuing novel research and product development programs. Our customers also include a range of government, academic and biotechnology institutions.

As of June 30, 2024, we employed a team of over 580 full-time employees, approximately 27% of whom have advanced degrees.

We primarily utilize a direct sales model for our sales to our customers in North America. Our international sales, primarily in Europe and Asia Pacific, are through a combination of third-party distributors as well as via a direct sales model. The percentage of our total revenue derived from customers in North America was 44.0% and 47.7% for the three and six months ended June 30, 2024, respectively. The percentage of our total revenue derived from customers in North America was 49.8% and 50.6% for the three and six months ended June 30, 2023, respectively.

We generated revenue of $73.4 million and $137.6 million for the three and six months ended June 30, 2024, respectively, and $68.9 million and $147.9 million for the three and six months ended June 30, 2023, respectively.

Total revenue by segment was $58.5 million in Nucleic Acid Production and $14.9 million in Biologics Safety Testing for the three months ended June 30, 2024, compared to $53.3 million and $15.6 million, respectively, for the three months ended June 30, 2023.

Total revenue by segment was $104.5 million in Nucleic Acid Production and $33.1 million in Biologics Safety Testing for the six months ended June 30, 2024, compared to $114.7 million and $33.2 million, respectively, for the six months ended June 30, 2023.

We focus a substantial portion of our resources supporting our core business segments. We are actively pursuing opportunities to expand our customer base both domestically and internationally by fostering strong relationships with both existing and new customers and distributors. Our management team has experience working with biopharmaceutical, vaccine, diagnostics and gene and cell therapy companies as well as academic and research scientists. We also intend to continue making investments in our overall infrastructure and business segments to support our growth. We incurred aggregate selling, general and administrative expenses of $40.6 million and $81.4 million for the three and six months ended June 30, 2024, respectively, and $35.4 million and $74.0 million for the three and six months ended June 30, 2023, respectively.

Our research and development efforts are geared towards supporting our customers’ needs. We incurred research and development expenses of $5.3 million and $10.3 million for the three and six months ended June 30, 2024, respectively, and $4.2 million and $8.3 million for the three and six months ended June 30, 2023, respectively. We intend to continue to invest in research and development and new products and technologies to support our customers’ needs for the foreseeable future.

Trends and Uncertainties

While we believe that the long-term trend of biopharmaceutical customers relying on outside parties to provide important inputs and services for their clinical research and manufacturing remains a long-term growth driver for us, we believe that recent industry trends and uncertainties, including changes in our customers’ spending priorities and budgetary policies and practices, which negatively impacted our revenue and operating results in the year ended December 31, 2023, may continue and result in slower growth and/or cause a further decline in our revenues during the year ending December 31, 2024. These trends and uncertainties, which we primarily attribute to lower levels of investment in the research and development funding of early-stage biotechnology companies and declines and uncertainties in the capital markets amidst ongoing negative macroeconomic challenges, has and may continue to cause those companies to take action to conserve capital, resulting in a potential reduction in research and development spending across the markets in which we participate.

Our businesses also continue to see headwinds from a general contraction in economic activity in Asia, particularly in China, which may negatively impact our revenue derived from those markets.

How We Assess Our Business

We consider a variety of financial and operating measures in assessing the performance of our business. The key measures we use to determine how our business is performing are revenue and Adjusted EBITDA.

Adjusted EBITDA is a non-GAAP financial performance measure that we define as net loss adjusted for interest, provision for income taxes, depreciation, amortization and stock-based compensation expenses. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items, that we do not consider representative of our ongoing operating performance.

Management uses Adjusted EBITDA to evaluate the financial performance of our business and the effectiveness of our business strategies. We present Adjusted EBITDA because we believe this performance measure is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and they facilitate comparisons of performance on a consistent basis across reporting periods. Further, we believe this performance measure is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance. Adjusted EBITDA is also a component of the financial covenant under the Credit Agreement that governs our ability to access more than $63.0 million in aggregate letters of credit and available borrowings under the Revolving Credit Facility. In addition, if we borrow more than $63.0 million under the Revolving Credit Facility, we are required to maintain a specified net leverage ratio. See “Liquidity and Capital Resources—Credit Agreement” below for a discussion of this financial covenant.

Adjusted EBITDA is not a GAAP-based measure and, therefore, may have limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. We may in the future incur expenses similar to the adjustments in the presentation of Adjusted EBITDA. In particular, we expect to incur meaningful share-based compensation expense in the future. Other limitations include that Adjusted EBITDA do not reflect:

  • all expenditures or future requirements for capital expenditures or contractual commitments;
  • changes in our working capital needs;
  • provision for income taxes, which may be a necessary element of our costs and ability to operate;
  • the costs of replacing the assets being depreciated, which will often have to be replaced in the future;
  • the non-cash component of employee compensation expense; and
  • the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations.

In addition, Adjusted EBITDA is not a measure of financial performance under GAAP and may not be comparable to similarly titled measures used by other companies in our industry or across different industries.

Components of Results of Operations

Revenue

Our revenue consists primarily of product revenue and, to a much lesser extent, service revenue. We generated total consolidated revenue of $73.4 million and $137.6 million for the three and six months ended June 30, 2024, respectively, and $68.9 million and $147.9 million for the three and six months ended June 30, 2023, respectively, through the following segments: (i) Nucleic Acid Production and (ii) Biologics Safety Testing.

Nucleic Acid Production Segment

Our Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Biologics Safety Testing Segment

Our Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by our customers in their biologic drug manufacturing activities.

Cost of Revenue

Cost of revenue associated with our products primarily consists of manufacturing related costs incurred in the production process, including personnel and related costs, stock-based compensation expense, inventory write-downs, costs of materials, labor and overhead, packaging and delivery costs and allocated costs, including facilities, information technology, depreciation and amortization of intangibles. Cost of revenue also includes adjustments for excess, obsolete or expired inventory, and idle capacity. Cost of revenue associated with our services primarily consists of personnel and related costs, stock-based compensation expense, cost of materials and allocated costs, including facilities and information technology costs. Costs of services were not material for the three and six months ended June 30, 2024 and 2023.

Operating Expenses

Selling, General and Administrative

Our selling, general and administrative expenses primarily consist of salaries, benefits and stock-based compensation expense for our employees in our commercial sales functions, marketing, executive, accounting and finance, legal and human resource functions as well as travel expenses, professional services fees, such as consulting, audit, tax and legal fees, general corporate costs and allocated costs, including facilities, information technology and amortization of intangibles.

We expect that our selling, general and administrative expenses will gradually increase in future periods, primarily due to our expanding facilities footprint to support anticipated long-term growth in the business, costs incurred in increasing our presence globally, and increases in marketing activities to drive awareness and adoption of our products and services.

Research and Development

Research and development costs primarily consist of salaries, benefits, stock-based compensation expense, outside contracted services, cost of supplies, in-process research and development costs from asset acquisitions and allocated facilities costs for employees engaged in research and development of products and services. We expense all research and development costs in the period in which they are incurred. Payment made prior to the receipt of goods or services to be used in research and development are recognized as prepaid assets until the goods are received or services are rendered.

We expect our research and development costs will increase to support our research and development efforts, including meeting our customers’ needs.

Change in Estimated Fair Value of Contingent Consideration

Change in estimated fair value of contingent consideration consists of fair value adjustments to contingent consideration liabilities associated with completed acquisitions. These adjustments are based on our assessment of the probability of achieving certain revenue thresholds and other probability factors.

Restructuring

For the six months ended June 30, 2024, restructuring costs (benefit) primarily consisted of the stock-based compensation benefit recognized for the forfeiture of stock awards upon the termination of certain impacted employees resulting from a Cost Realignment Plan, which was implemented in November 2023.

Other Income (Expense)

Interest Expense

Interest expense consists of interest costs and the related amortization of the debt discount and deferred issuance costs on our outstanding debt, changes in the fair value of our interest rate cap agreement, and interest costs on our finance lease liabilities.

Interest Income

Interest income consists of interest earned on our cash balances and short-term investments in money market funds held at financial institutions.

Change in Payable to Related Parties Pursuant to the Tax Receivable Agreement

The Tax Receivable Agreement liability adjustment reflects changes in the Tax Receivable Agreement liability recorded in our condensed consolidated balance sheets primarily due to changes in our estimated state apportionment and the corresponding change of our estimated state tax rate.

Income Tax Expense (Benefit)

As a result of our ownership of LLC Units in Topco LLC, we are subject to U.S. federal, state and local income taxes with respect to our allocable share of any taxable income of Topco LLC and will be taxed at the prevailing corporate tax rates.

Non-Controlling Interests

Non-controlling interests represent the portion of profit or loss, net assets and comprehensive income or loss of our consolidated subsidiaries that is not allocable to the Company based on our percentage of ownership of such entities. Income or loss attributed to the non-controlling interests is based on the LLC Units outstanding during the period and is presented on the condensed consolidated statements of operations. As of June 30, 2024, we held approximately 56.1% of the outstanding LLC Units of Topco LLC, and MLSH 1 held approximately 43.9% of the outstanding LLC Units of Topco LLC.

Results of Operations

The results of operations presented below should be reviewed in conjunction with the condensed consolidated financial statements and notes included elsewhere in this Quarterly Report on Form 10-Q. For information with respect to recent accounting pronouncements that are of significance or potential significance to us, see Note 1 to the condensed consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.

(in thousands, except per share amounts)

Three Months Ended June 30, 2024 2023 Change
Revenue $73,400 $68,914 6.5%
Operating expenses:
Cost of revenue (1) 38,271 43,273 (11.6)%
Selling, general and administrative (1) 40,556 35,377 14.6%
Research and development (1) 5,284 4,194 26.0%
Change in estimated fair value of contingent consideration (1,195) (2,316) (48.4)%
Restructuring (1) (4) — *
Total operating expenses 82,912 80,528 3.0%
Loss from operations (9,512) (11,614) (18.1)%
Other income (expense), net (7,415) (1,750) 323.7%
Loss before income taxes (16,927) (13,364) 26.7%
Income tax benefit (2,435) (1,421) 71.4%
Net loss (14,492) (11,943) 21.3%
Net loss attributable to non-controlling interests (6,907) (5,402) 27.9%
Net loss attributable to Maravai LifeSciences Holdings, Inc. $(7,585) $(6,541) 16.0%
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic and diluted $(0.05) $(0.05)
Weighted average number of Class A common shares outstanding, basic and diluted 135,842 131,864
Adjusted EBITDA (Non-GAAP financial measure) $16,917 $9,077

31

(in thousands, except per share amounts)

Six Months Ended June 30, 2024 2023 Change
Revenue $137,579 $147,939 (7.0)%
Operating expenses:
Cost of revenue (1) 76,606 76,949 (0.4)%
Selling, general and administrative (1) 81,441 74,048 10.0%
Research and development (1) 10,316 8,339 23.7%
Change in estimated fair value of contingent consideration (1,195) (2,316) (48.4)%
Restructuring (1) (1,216) — *
Total operating expenses 165,952 157,020 5.7%
Loss from operations (28,373) (9,081) 212.4%
Other income (expense), net (10,963) (8,806) 24.5%
Loss before income taxes (39,336) (17,887) 119.9%
Income tax benefit (2,164) (4,596) (52.9)%
Net loss (37,172) (13,291) 179.7%
Net loss attributable to non-controlling interests (17,509) (6,683) 162.0%
Net loss attributable to Maravai LifeSciences Holdings, Inc. $(19,663) $(6,608) 197.6%
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic and diluted $(0.15) $(0.05)
Weighted average number of Class A common shares outstanding, basic and diluted 134,088 131,802
Adjusted EBITDA (Non-GAAP financial measure) $24,712 $32,875

* Not meaningful

(1) Includes stock-based compensation expense (benefit) as follows (in thousands, except percentages):

Three Months Ended June 30, 2024 2023 Change
Cost of revenue $2,700 $2,168 24.5%
Selling, general and administrative 9,800 6,351 54.3%
Research and development 1,259 753 67.2%
Restructuring 4 — *
Total stock-based compensation expense $13,763 $9,272 48.4%
Six Months Ended June 30, 2024 2023 Change
Cost of revenue $5,331 $3,507 52.0%
Selling, general and administrative 19,300 10,553 82.9%
Research and development 2,416 1,199 101.5%
Restructuring (1,227) — *
Total stock-based compensation expense $25,820 $15,259 69.2%

32

Revenue

Consolidated revenue by segment was as follows for the periods presented (in thousands, except percentages):

Three Months Ended June 30, 2024 2023 Change Percentage of Revenue 2024 2023
Nucleic Acid Production $58,483 $53,265 9.8% 79.7% 77.3%
Biologics Safety Testing 14,917 15,649 (4.7)% 20.3% 22.7%
Total revenue $73,400 $68,914 6.5% 100.0% 100.0%
Six Months Ended June 30, 2024 2023 Change Percentage of Revenue 2024 2023
Nucleic Acid Production $104,499 $114,716 (8.9)% 76.0% 77.5%
Biologics Safety Testing 33,080 33,223 (0.4)% 24.0% 22.5%
Total revenue $137,579 $147,939 (7.0)% 100.0% 100.0%

Comparison of Three Months Ended June 30, 2024 and 2023

Total revenue was $73.4 million for the three months ended June 30, 2024 compared to $68.9 million for the three months ended June 30, 2023, representing an increase of $4.5 million, or 6.5%.

Nucleic Acid Production revenue increased from $53.3 million for the three months ended June 30, 2023 to $58.5 million for the three months ended June 30, 2024, representing an increase of $5.2 million, or 9.8%. The increase in Nucleic Acid Production revenue was primarily driven by higher demand for GMP CleanCap analogs, GMP mRNA, and our Glen Research product portfolio.

Biologics Safety Testing revenue decreased from $15.6 million for the three months ended June 30, 2023 to $14.9 million for the three months ended June 30, 2024, representing a decrease of $0.7 million, or 4.7%. The decrease from the prior year was primarily due to lower demand trends in China.

Comparison of Six Months Ended June 30, 2024 and 2023

Total revenue was $137.6 million for the six months ended June 30, 2024 compared to $147.9 million for the six months ended June 30, 2023, representing a decrease of $10.4 million, or 7.0%.

Nucleic Acid Production revenue decreased from $114.7 million for the six months ended June 30, 2023 to $104.5 million for the six months ended June 30, 2024, representing a decrease of $10.2 million, or 8.9%. The decrease in Nucleic Acid Production revenue was primarily due to lower demand in research and discovery products and timing of GMP-related mRNA builds for customers.

Biologics Safety Testing revenue decreased from $33.2 million for the six months ended June 30, 2023 to $33.1 million for the six months ended June 30, 2024, representing a decrease of $0.1 million, or 0.4%, which was not significant.

Segment Information

Management has determined that adjusted earnings before interest, tax, depreciation and amortization is the profit or loss measure used to make resource allocation decisions and evaluate segment performance. Adjusted EBITDA assists management in comparing the segment performance on a consistent basis for purposes of business decision-making by removing the impact of certain items that management believes do not directly reflect the core operations and, therefore, are not included in measuring segment performance. We define Adjusted EBITDA as net loss before interest, taxes, depreciation and amortization, certain non-cash items and other adjustments that we do not consider in our evaluation of ongoing operating performance from period to period. Corporate costs, net of eliminations, are managed on a standalone basis and are not allocated to segments.

We do not allocate assets to our reportable segments as they are not included in the review performed by our Chief Operating Decision Maker for purposes of assessing segment performance and allocating resources.

As of June 30, 2024, all of our long-lived assets were located within the United States.

The following schedule includes revenue and adjusted EBITDA for each of our reportable operating segments (in thousands):

Revenue: Three Months Ended June 30, 2024 2023 Six Months Ended June 30, 2024 2023
Nucleic Acid Production $58,483 $53,265 $104,499 $114,716
Biologics Safety Testing 14,917 15,651 33,080 33,225
Total reportable segments’ revenue 73,400 68,916 137,579 147,941
Intersegment eliminations — (2) — (2)
Total $73,400 $68,914 $137,579 $147,939
Segment adjusted EBITDA:
Nucleic Acid Production $21,301 $14,192 $31,389 $42,065
Biologics Safety Testing 9,445 10,315 23,371 24,061
Total reportable segments’ adjusted EBITDA 30,746 24,507 54,760 66,126
Reconciliation of total reportable segments’ adjusted EBITDA to loss before income taxes
Amortization (6,869) (6,852) (13,738) (13,617)
Depreciation (5,556) (2,815) (10,342) (4,895)
Interest expense (11,939) (7,022) (22,803) (18,855)
Interest income 7,086 6,791 14,296 12,836
Corporate costs, net of eliminations (13,829) (15,430) (30,048) (33,251)
Other adjustments:
Acquisition contingent consideration 1,195 2,316 1,195 2,316
Acquisition integration costs (1,224) (3,466) (3,722) (5,930)
Stock-based compensation (13,763) (9,272) (25,820) (15,259)
Merger and acquisition related expenses — (371) (30) (3,662)
Acquisition related tax adjustment (2,554) (1,620) (2,441) (1,447)
Tax Receivable Agreement liability adjustment — 101 — (1,335)
Restructuring costs (1) 8 — (11) —
Other (228) (231) (632) (914)
Loss before income taxes (16,927) (13,364) (39,336) (17,887)
Income tax benefit 2,435 1,421 2,164 4,596
Net loss $(14,492) $(11,943) $(37,172) $(13,291)

(1) For the three months ended June 30, 2024, there was an immaterial amount of stock-based compensation expense in connection with the restructuring included in the stock based-compensation line item. For the six months ended June 30, 2024, stock-based compensation benefit of $1.2 million related to forfeited stock awards in connection with the restructuring is included on the stock-based compensation line item.

There was no intersegment revenue during the three and six months ended June 30, 2024. During the three and six months ended June 30, 2023, intersegment revenue was immaterial between the Nucleic Acid Production and Biologics Safety Testing segments. Any intersegment revenue and the related gross margin on inventory recorded at the end of the period are eliminated for consolidation purposes. Internal selling prices for intersegment sales are consistent with the segment’s normal retail price offered to external parties. There was no commission expense recognized for intersegment revenue for each of the three and six months ended June 30, 2024 and 2023.

Adjusted EBITDA (Non-GAAP Financial Measure)

A reconciliation of net loss to adjusted EBITDA, which is a non-GAAP financial performance measure, is set forth below (in thousands):

Three Months Ended June 30, 2024 2023 Six Months Ended June 30, 2024 2023
Net loss $(14,492) $(11,943) $(37,172) $(13,291)
Add:
Amortization 6,869 6,852 13,738 13,617
Depreciation 5,556 2,815 10,342 4,895
Interest expense 11,939 7,022 22,803 18,855
Interest income (7,086) (6,791) (14,296) (12,836)
Income tax benefit (2,435) (1,421) (2,164) (4,596)
EBITDA 351 (3,466) (6,749) 6,644
Acquisition contingent consideration (1) (1,195) (2,316) (1,195) (2,316)
Acquisition integration costs (2) 1,224 3,466 3,722 5,930
Stock-based compensation (3) 13,763 9,272 25,820 15,259
Merger and acquisition related expenses (4) — 371 30 3,662
Acquisition related tax adjustment (5) 2,554 1,620 2,441 1,447
Tax Receivable Agreement liability adjustment (6) — (101) — 1,335
Restructuring costs (7) (8) — 11 —
Other (8) 228 231 632 914
Adjusted EBITDA $16,917 $9,077 $24,712 $32,875

(1) Refers to the change in estimated fair value of contingent consideration related to completed acquisitions.

(2) Refers to incremental costs incurred to execute and integrate completed acquisitions, and retention payments in connection with these acquisitions.

(3) Refers to non-cash expense associated with stock-based compensation.

(4) Refers to diligence, legal, accounting, tax and consulting fees incurred associated with acquisitions that were pursued but not consummated.

(5) Refers to non-cash expense associated with adjustments to the indemnification asset recorded in connection with the acquisition of MyChem, LLC (“MyChem”), which was completed in January 2022.

(6) Refers to the adjustment of the Tax Receivable Agreement liability primarily due to changes in our estimated state apportionment and the corresponding change of our estimated state tax rate.

(7) Refers to restructuring costs (benefit) associated with the Cost Realignment Plan, which was implemented in November 2023. For the six months ended June 30, 2024, stock-based compensation benefit of $1.2 million related to forfeited stock awards in connection with the restructuring is included on the stock-based compensation line item. For the three months ended June 30, 2024, such amount was immaterial.

(8) For the three and six months ended June 30, 2024, refers to severance payments, inventory step-up charges and certain other adjustments in connection with the acquisition of Alphazyme, LLC (“Alphazyme”), which was completed in January 2023, and other non-recurring costs. For the three and six months ended June 30, 2023, refers to severance payments, legal settlement amounts, inventory step-up charges in connection with the acquisition of Alphazyme, certain working capital and other adjustments related to the acquisition of MyChem, and other non-recurring costs.

Operating Expenses

Operating expenses included the following for the periods presented (in thousands, except percentages):

Three Months Ended June 30, 2024 2023 Change Percentage of Revenue 2024 2023
Cost of revenue $38,271 $43,273 (11.6)% 52.1% 62.8%
Selling, general and administrative 40,556 35,377 14.6% 55.3% 51.3%
Research and development 5,284 4,194 26.0% 7.2% 6.1%
Change in estimated fair value of contingent consideration (1,195) (2,316) (48.4)% (1.6)% (3.3)%
Restructuring (4) — * 0.0% —%
Total operating expenses $82,912 $80,528 3.0% 113.0% 116.9%
Six Months Ended June 30, 2024 2023 Change Percentage of Revenue 2024 2023
Cost of revenue $76,606 $76,949 (0.4)% 55.7% 52.0%
Selling, general and administrative 81,441 74,048 10.0% 59.2% 50.1%
Research and development 10,316 8,339 23.7% 7.5% 5.6%
Change in estimated fair value of contingent consideration (1,195) (2,316) (48.4)% (0.9)% (1.6)%
Restructuring (1,216) — * (0.9)% —%
Total operating expenses $165,952 $157,020 5.7% 120.6% 106.1%

* Not meaningful

Cost of Revenue

Comparison of Three Months Ended June 30, 2024 and 2023

Cost of revenue decreased by $5.0 million from $43.3 million for the three months ended June 30, 2023 to $38.3 million for the three months ended June 30, 2024, or 11.6%. The decrease in cost of revenue was primarily attributable to a decrease of $8.7 million due to lower direct labor and overhead expense absorption and a decrease of $1.7 million in personnel costs primarily driven by a decrease in retention payment expense associated with the acquisition of MyChem. These decreases were partially offset by increases of $2.9 million in direct product costs, $0.7 million in depreciation expense, $0.7 million in supplies and materials, $0.5 million in stock-based compensation expense, and $0.3 million in facilities costs.

Gross profit margin increased by 10.7% from 37.2% for the three months ended June 30, 2023 to 47.9% for the three months ended June 30, 2024. The increase in the gross profit margin was primarily attributable to an overall decrease in the cost of revenue as a percentage of sales as the result of lower personnel costs and lower direct labor and overhead expense absorption incurred into cost of revenue in the period.

Comparison of Six Months Ended June 30, 2024 and 2023

Cost of revenue decreased by $0.3 million from $76.9 million for the six months ended June 30, 2023 to $76.6 million for the six months ended June 30, 2024, or 0.4%. The decrease in cost of revenue from the prior year was not significant.

Gross profit margin decreased by 3.7% from 48.0% for the six months ended June 30, 2023 to 44.3% for the six months ended June 30, 2024. The decrease in the gross profit margin was primarily attributable to an overall increase in the cost of revenue as a percentage of sales as the result of higher supplies and materials, higher stock-based compensation expense, higher depreciation expense, and lower manufacturing throughput and related absorption which increased the overall direct labor and overhead expenses incurred into cost of revenue in the period.

Selling, General and Administrative

Comparison of Three Months Ended June 30, 2024 and 2023

Selling, general and administrative expenses increased by $5.2 million from $35.4 million for the three months ended June 30, 2023 to $40.6 million for the three months ended June 30, 2024, or 14.6%. The increase was primarily driven by increases of $3.4 million in stock-based compensation expense and $2.0 million in depreciation expense driven by new facilities and an increase in assets placed in service during the current year.

Comparison of Six Months Ended June 30, 2024 and 2023

Selling, general and administrative expenses increased by $7.4 million from $74.0 million for the six months ended June 30, 2023 to $81.4 million for the six months ended June 30, 2024, or 10.0%. The increase was primarily driven by increases of $8.7 million in stock-based compensation expense, $4.5 million in depreciation expense driven by new facilities and an increase in assets placed in service during the current year, and $0.4 million in certain adjustments related to the acquisition of MyChem recognized in the prior period. These were partially offset by a decrease of $6.8 million in professional service fees driven by consulting services incurred in the prior period primarily related to merger and acquisition related expenses and contract services.

Research and Development

Comparison of Three Months Ended June 30, 2024 and 2023

Research and development expenses increased by $1.1 million from $4.2 million for the three months ended June 30, 2023 to $5.3 million for the three months ended June 30, 2024, or 26.0%. The increase in expenses compared to the prior year was primarily driven by increases of $0.9 million in supplies and materials primarily for chemicals, $0.5 million in stock-based compensation expense, and $0.4 million for professional service fees for external analytic studies. These were partially offset by a decrease of $0.7 million in personnel costs.

Comparison of Six Months Ended June 30, 2024 and 2023

Research and development expenses increased by $2.0 million from $8.3 million for the six months ended June 30, 2023 to $10.3 million for the six months ended June 30, 2024, or 23.7%. The increase in expenses compared to the prior year was primarily driven by increases of $1.2 million in stock-based compensation expense and $0.9 million in professional service fees for external analytic studies.

Change in Estimated Fair Value of Contingent Consideration

Comparison of Three and Six Months Ended June 30, 2024 and 2023

The decrease in change in estimated fair value of contingent consideration of $1.1 million for the three and six months ended June 30, 2023 was due to a decrease in estimated fair value of the liability for the contingent payments associated with the acquisition of Alphazyme.

Restructuring

Comparison of Three Months Ended June 30, 2024 and 2023

For the three months ended June 30, 2024, restructuring charges were not significant.

Comparison of Six Months Ended June 30, 2024 and 2023

For the six months ended June 30, 2024, restructuring costs (benefit) primarily consists of the stock-based compensation benefit recognized for the forfeiture of stock awards upon the termination of certain impacted employees resulting from a Cost Realignment Plan, which was implemented in November 2023.

Other Income (Expense)

Other income (expense) included the following for the periods presented (in thousands, except percentages):

Three Months Ended June 30, 2024 2023 Change Percentage of Revenue 2024 2023
Interest expense $(11,939) $(7,022) 70.0% (16.3)% (10.2)%
Interest income 7,086 6,791 4.3% 9.7% 10.0%
Change in payable to related parties pursuant to the Tax Receivable Agreement — 101 * —% 0.1%
Other expense (2,562) (1,620) 58.1% (3.5)% (2.4)%
Total other expense $(7,415) $(1,750) 323.7% (10.1)% (2.5)%
Six Months Ended June 30, 2024 2023 Change Percentage of Revenue 2024 2023
Interest expense $(22,803) $(18,855) 20.9% (16.6)% (12.8)%
Interest income 14,296 12,836 11.4% 10.4% 8.7%
Change in payable to related parties pursuant to the Tax Receivable Agreement — (1,335) * —% (0.9)%
Other expense (2,456) (1,452) 69.1% (1.8)% (1.0)%
Total other expense $(10,963) $(8,806) 24.5% (8.0)% (6.0)%

* Not meaningful

Comparison of Three Months Ended June 30, 2024 and 2023

Other expense was $1.8 million for the three months ended June 30, 2023 compared to $7.4 million for the three months ended June 30, 2024, representing an increase of $5.7 million, or 323.7%. The increase was primarily attributable to a $4.9 million increase in interest expense primarily due to changes in the fair value of our interest rate cap agreement. The increase was further driven by $0.9 million relating to adjustments to the indemnification asset recorded in connection with the acquisition of MyChem.

Comparison of Six Months Ended June 30, 2024 and 2023

Other expense was $8.8 million for the six months ended June 30, 2023 compared to $11.0 million for the six months ended June 30, 2024, representing an increase of $2.2 million, or 24.5%. The increase in was primarily attributable to a $3.9 million increase in interest expense primarily due to changes in the fair value of our interest rate cap agreement and a higher effective interest rate. The increase was further driven by a $1.0 million adjustment to the indemnification asset recorded in connection with the acquisition of MyChem. These increases were offset by the change in payable to related parties pursuant to the Tax Receivable Agreement of $1.3 million in the prior year as a result of changes in our estimated state income tax apportionment and a corresponding change in our estimated state income tax rate, and a $1.5 million increase in interest income earned on our cash and cash equivalent balances, which included short-term investments in money market funds.

Relationship with GTCR, LLC (“GTCR”)

As of June 30, 2024, investment entities affiliated with GTCR collectively controlled approximately 52% of the voting power of our common stock, which enables GTCR to control the vote of all matters submitted to a vote of our shareholders and to control the election of members of the Board and all other corporate decisions.

We made distributions of $0.6 million during each of the three and six months ended June 30, 2024, and $1.3 million and $9.6 million during the three and six months ended June 30, 2023, respectively, for tax liabilities to MLSH 1, which is controlled by investment entities affiliates with GTCR and is the only holder of LLC Units other than us and our wholly owned subsidiaries.

We are also a party to a Tax Receivable Agreement, or TRA, with MLSH 1, which is primarily owned by GTCR, and MLSH 2 (see Note 10 to the condensed consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q). The TRA provides for the payment by us to MLSH 1 and MLSH 2, collectively, of 85% of the amount of tax benefits, if any, that we actually realize, or in some circumstances are deemed to realize, from exchanges of LLC Units (together with the corresponding shares of Class B common stock) for Class A common stock, as a result of (i) certain increases in the tax basis of assets of Topco LLC and its subsidiaries resulting from purchases or exchanges of LLC Units, (ii) certain tax attributes of the entities acquired from MLSH 1 and MLSH 2 in connection with the Organizational Transactions, Topco LLC and subsidiaries of Topco LLC that existed prior to the IPO, and (iii) certain other tax benefits related to our entering into the TRA, including tax benefits attributable to payments that we make under the TRA (collectively, the “Tax Attributes”). Payment obligations under the TRA are not conditioned upon any Topco LLC unitholders maintaining a continued ownership interest in us or Topco LLC, and the rights of MLSH 1 and MLSH 2 under the TRA are assignable. There is no stated term for the TRA, and the TRA will continue until all tax benefits have been utilized or expired unless we exercise our right to terminate the TRA for an agreed-upon amount.

We recognize the amount of TRA payments expected to be paid within the next 12 months and classify this amount as current. As of June 30, 2024, our current liability under the TRA was $7.1 million.

As of December 31, 2023, the Company had derecognized the remaining $665.3 million non-current liability under the TRA after concluding it was not probable that the Company will be able to realize the remaining tax benefits based on estimates of future taxable income. There have been no changes to our position from those set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The impact of any activity for the fiscal year ending December 31, 2024, including any exchanges or changes to our estimated state tax rate, will be included in our Annual Report on Form 10-K for the fiscal year ending December 31, 2024 when amounts are determinable. The estimation of liability under the TRA is by its nature imprecise and subject to significant assumptions regarding the amount, character, and timing of the taxable income in the future. If the Company concludes in a future period that the tax benefits are more likely than not to be realized and releases its valuation allowance, the corresponding TRA liability amounts may be considered probable at that time and recorded on the consolidated balance sheet and within earnings.

We made payments of $42.6 million in the aggregate to MLSH 1 and MLSH 2 pursuant to the TRA during each of the three and six months ended June 30, 2023, of which $0.4 million was related to interest. No such payments were made during each of the three and six months ended June 30, 2024.

Liquidity and Capital Resources

Overview

We have financed our operations primarily from cash flow from operations, borrowings under long-term debt agreements and, to a lesser extent, the sale of our Class A common stock.

As of June 30, 2024, we had cash and cash equivalents of $573.2 million and retained earnings of $266.1 million. We had positive cash flow from operations of $9.0 million for the six months ended June 30, 2024.

We have historically relied on revenue derived from product and services sales, and proceeds from equity and debt financings to fund our operations to date.

Our principal uses of cash have been to fund operations, acquisitions and capital expenditures, as well as make tax distributions to MLSH 1, make TRA payments to MLSH 1 and MLSH 2 and make interest payments and mandatory principal payments on our long-term debt.

We plan to utilize our existing cash on hand, together with cash generated from operations, primarily to fund our commercial and marketing activities associated with our products and services, continued research and development initiatives, and ongoing investments into our manufacturing facilities to create efficiencies and build capacity. We believe our cash on hand, cash generated from operations and continued access to our credit facilities, will be sufficient to satisfy our cash requirements over the next 12 months and beyond.

As a result of our ownership of LLC Units in Topco LLC, the Company is subject to U.S. federal, state and local income taxes with respect to its allocable share of any taxable income of Topco LLC and is taxed at the prevailing corporate tax rates. In addition to tax expenses, we also will incur expenses related to our operations and we may be required to make payments under the TRA with MLSH 1 and MLSH 2. Due to the uncertainty of various factors, we cannot precisely quantify the likely tax benefits we will realize as a result of LLC Unit exchanges and the resulting amounts we are likely to pay out to LLC Unitholders of Topco LLC pursuant to the TRA. The foregoing numbers are estimates and the actual payments could differ materially. We expect to fund these payments using cash on hand and cash generated from operations. We expect that probable future payments under the TRA relating to the purchase by the Company of LLC Units from MLSH 1 and the corresponding tax attributes will be approximately $7.1 million. This determination is based on our estimate of taxable income for the year ended December 31, 2023.

During the year ended December 31, 2023, we determined that making a payment under the non-current portion of the TRA was not probable under Accounting Standards Codification 450 - Contingencies as a result of a valuation allowance having been recorded against our deferred tax assets and, therefore, that it is more likely than not that we will not generate sufficient future taxable income to utilize related tax benefits that will result in a payment under the TRA. There have been no changes to our position from those set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The impact of any activity for the fiscal year ending December 31, 2024, including any exchanges or changes to our estimated state tax rate, will be included in our Annual Report on Form 10-K for the fiscal year ending December 31, 2024 when amounts are determinable.

As a result of a change of control, material breach, or our election to terminate the TRA early, (1) we could be required to make cash payments to MLSH 1 and MLSH 2 that are greater than the specified percentage of the actual benefits we ultimately realize in respect of the tax benefits that are subject to the TRA, and (2) we will be required to make an immediate cash payment equal to the present value of the anticipated future tax benefits that are the subject of the TRA, which payment may be made significantly in advance of the actual realization, if any, of such future tax benefits. In these situations, our obligations under the TRA could have a material adverse effect on our liquidity and could have the effect of delaying, deferring or preventing certain mergers, asset sales, other forms of business combinations, or other changes of control. There can be no assurance that we will be able to finance our obligations under the TRA.

In addition to payments to be made under the TRA, we are also required to make tax distributions to MLSH 1 pursuant to the LLC Operating Agreement for the portion of income passing through to them from Topco LLC. We made cash distributions of $0.6 million during each of the three and six months ended June 30, 2024, and cash distributions of $1.3 million and $9.6 million during the three and six months ended June 30, 2023, respectively, for tax liabilities to MLSH 1 under the LLC Operating Agreement.

Credit Agreement

In October 2020, Maravai Intermediate Holdings, LLC (“Intermediate”), a wholly-owned subsidiary of Topco LLC, along with certain of its subsidiaries (together with Intermediate, the “Borrowers”), entered into a credit agreement (as amended, the “Credit Agreement”), which provides for a term loan facility and a revolving credit facility. In January 2022, the Company entered into an amendment (the “Amendment”) to refinance the term loan and to replace London Interbank Offered Rate (“LIBOR”) with a Term Secured Overnight Financing Rate (“SOFR”) based rate.

As amended, the Credit Agreement provides for a $600.0 million term loan facility, maturing October 2027 (the “Term Loan”), and a $180.0 million revolving credit facility (the “Revolving Credit Facility”).

As of June 30, 2024, the effective interest rate on the Term Loan was 8.33% per annum. There were no outstanding borrowings under the Revolving Credit Facility as of June 30, 2024.

The Credit Agreement also provides availability under the Revolving Credit Facility for letters of credit with a limit of $20.0 million. As of June 30, 2024, the Company had a $0.5 million outstanding letter of credit as security for a lease agreement, which reduced the availability for letters of credit under the Revolving Credit Facility to $19.5 million.

Borrowings under the Credit Agreement are unconditionally guaranteed by Topco LLC, together with the existing and future material domestic subsidiaries of Topco LLC (subject to certain exceptions), as specified in the respective guaranty agreements. Borrowings under the Credit Agreement are also secured by a first-priority lien and security interest in substantially all of the assets (subject to certain exceptions) of existing and future material domestic subsidiaries of Topco LLC that are loan parties.

The Term Loan requires mandatory quarterly principal payments of $1.4 million which began in March 2022, with all remaining outstanding principal due on maturity in October 2027.

Commencing with the fiscal year ended December 31, 2021, and each fiscal year thereafter, the Credit Agreement requires that we make mandatory prepayments on the Term Loan principal upon certain excess cash flow, subject to certain step-downs based on the Company’s first lien net leverage ratio. The excess cash flow shall be reduced to 25% or 0% of the calculated excess cash flow if the Company’s first lien net leverage ratio was equal to or less than 4.75:1.00 or 4.25:1.00, respectively, however, no prepayment shall be required to the extent excess cash flow calculated for the respective period is equal to or less than $10.0 million. As of June 30, 2024, the Company’s first lien net leverage ratio was less than 4.25:1.00. Thus, a mandatory prepayment on the Term Loan out of our excess cash flow was not required.

The Credit Agreement contains certain covenants, including, among other things, covenants limiting our ability to incur or prepay certain indebtedness, pay dividends or distributions, dispose of assets, engage in mergers and consolidations, make acquisitions or other investments and make changes to the nature of the business. Additionally, the Credit Agreement requires us to maintain a certain net leverage ratio if the outstanding debt balance on the Revolving Credit Facility exceeds 35.0% of the aggregate amount of available credit of $180.0 million, or $63.0 million. The Company was in compliance with these covenants as of June 30, 2024.

Tax Receivable Agreement

We are a party to the TRA with MLSH 1 and MLSH 2. The TRA provides for the payment by us to MLSH 1 and MLSH 2, collectively, of 85% of the amount of certain tax benefits, if any, that we actually realize, or in some circumstances are deemed to realize, as a result of the Organizational Transactions, IPO and any subsequent purchases or exchanges of LLC Units of Topco LLC.

As of June 30, 2024, our current liability under the TRA was $7.1 million, representing 85% of the calculated tax savings we expect to utilize for the year ended December 31, 2023. We may record additional liabilities under the TRA when LLC Units are exchanged in the future and as our estimates of the future utilization of the Tax Attributes, net operating losses and other tax benefits change. We expect to make payments under the TRA, to the extent they are required, within 125 days after the extended due date of our U.S. federal income tax return for such taxable year. Interest on such payments will begin to accrue from the due date (without extensions) of such tax return at a rate of LIBOR (or, if LIBOR ceases to be published, a Replacement Rate) plus 100 basis points. Generally, any late payments will continue to accrue interest at LIBOR (or a Replacement Rate, as applicable) plus 500 basis points until such payments are made. Given the cessation of LIBOR, we have transitioned to the Secured Overnight Financing Rate ("SOFR") as the applicable Replacement Rate as allowable under the Tax Receivable Agreement.

The payment obligations under the TRA are obligations of Maravai LifeSciences Holdings, Inc. and not of Topco LLC. Although the actual timing and amount of any payments that may be made under the TRA will vary, the aggregate payments that we will be required to make to MLSH 1 and MLSH 2 may be substantial. Any payments made by us under the TRA will generally reduce the amount of overall cash flow that might have otherwise been available to us or to Topco LLC and, to the extent that we are unable to make payments under the TRA for any reason, the unpaid amounts will be deferred and will accrue interest until paid by us. We anticipate funding ordinary course payments under the TRA from cash flow from operations of Topco LLC and its subsidiaries, available cash and/or available borrowings under the Credit Agreement.

During the year ended December 31, 2023, we determined that making a payment under the non-current portion of the TRA was not probable under Accounting Standards Codification 450 - Contingencies as a result of a valuation allowance having been recorded against our deferred tax assets, and therefore, that it is more likely than not that we will not generate sufficient future taxable income to utilize related tax benefits that would result in a payment under the TRA. There have been no changes to our position from those set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The impact of any activity for the fiscal year ending December 31, 2024, including any exchanges or changes to our estimated state tax rate, will be included in our Annual Report on Form 10-K for the fiscal year ending December 31, 2024 when amounts are determinable.

Cash Flows

The following table summarizes our cash flows for the periods presented (in thousands):

Net cash provided by (used in): Six Months Ended June 30, 2024 2023
Operating activities $8,967 $104,268
Investing activities (10,426) (93,887)
Financing activities (332) (62,343)
Net decrease in cash and cash equivalents $(1,791) $(51,962)

Operating Activities

Net cash provided by operating activities for the six months ended June 30, 2024 was $9.0 million, which was primarily attributable to non-cash depreciation and amortization of $24.1 million, non-cash amortization of operating lease right-of-use assets of $4.2 million, non-cash amortization of deferred financing costs of $1.5 million, and non-cash stock-based compensation of $25.8 million. These were partially offset by a net loss of $37.2 million, non-cash gain on the change in estimated fair value of contingent consideration of $1.2 million, and net cash outflow from the change in our operating assets and liabilities of $8.4 million, of which $19.4 million was driven by a decrease in accrued expenses and other current liabilities for the retention payments relating to the acquisition of MyChem.

Net cash provided by operating activities for the six months ended June 30, 2023 was $104.3 million, which was primarily attributable to a net cash inflow from the change in our operating assets and liabilities of $86.9 million, non-cash depreciation and amortization of $18.5 million, non-cash amortization of operating lease right-of-use assets of $4.2 million, non-cash amortization of deferred financing costs of $1.4 million, non-cash stock-based compensation of $15.3 million, and non-cash loss on the revaluation of liabilities under the TRA of $1.3 million. These were partially offset by a net loss of $13.3 million, non-cash gain on the change in estimated fair value of contingent consideration of $2.3 million, and non-cash deferred income taxes of $4.3 million.

Investing Activities

Net cash used in investing activities for the six months ended June 30, 2024 was $10.4 million, which was primarily comprised of cash outflows of $15.2 million for property and equipment purchases, offset by proceeds from government assistance allocated to property and equipment of $4.8 million.

Net cash used in investing activities for the six months ended June 30, 2023 was $93.9 million, which was primarily comprised of the net cash consideration paid for the acquisition of Alphazyme and cash outflows of $32.9 million for property and equipment purchases, offset by proceeds from government assistance allocated to property and equipment of $8.7 million.

Financing Activities

Net cash used in financing activities for the six months ended June 30, 2024 was $0.3 million, which was primarily attributable to $1.5 million of tax payments for shares withheld under employee equity plans, net of proceeds from the issuance of shares of our Class A common stock, $2.7 million of principal repayments of long-term debt, and $0.6 million of cash distributions for tax liabilities to MLSH 1, as required pursuant to the terms of the LLC Operating Agreement. These were partially offset by proceeds from the interest rate cap agreement of $4.7 million.

Net cash used in financing activities for the six months ended June 30, 2023 was $62.3 million, which was primarily attributable to $42.2 million of payments to MLSH 1 and MLSH 2 pursuant to the TRA, $9.7 million payment of an acquisition consideration holdback relating to the acquisition of MyChem, $9.6 million of distributions for tax liabilities to non-controlling interest holders, required pursuant to the terms of the LLC Operating Agreement, and $2.7 million of principal repayments of long-term debt. This was partially offset by proceeds from the interest rate cap agreement of $1.9 million.

Capital Expenditures

Capital expenditures for the six months ended June 30, 2024 totaled $10.4 million, which is net of government funding under the Cooperative Agreement of $4.8 million. Capital expenditures for the year ending December 31, 2024 are projected to be approximately $30.0 million, which is net of anticipated government funding recognized. This primarily includes leasehold improvements and equipment primarily for the Flanders San Diego Facility.

Contractual Obligations and Commitments

The following table summarizes our contractual obligations and commitments as of June 30, 2024 (in thousands):

Payments due by period Total 1 year 2 - 3 years 4 - 5 years 5+ years
Operating leases (1) $60,445 $10,357 $19,525 $17,399 $13,164
Finance leases (2) 32,871 3,377 7,060 7,490 14,944
Debt obligations (3) 530,400 5,440 10,880 514,080 —
TRA payments (4) 7,069 7,069 — — —
Unconditional purchase obligations (5) 2,000 2,000 — — —
Total $632,785 $28,243 $37,465 $538,969 $28,108

(1) Represents operating lease payment obligations, excluding any renewal options we are reasonably certain to execute and have recognized as lease liabilities.

(2) Represents finance lease payment obligations, excluding any renewal options we are reasonably certain to execute and have recognized as lease liabilities.

(3) Represents long-term debt principal maturities, excluding interest. See Note 7 to the condensed consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information.

(4) Reflects the estimated timing of the current TRA liability payment as of June 30, 2024. See Note 10 to the condensed consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information regarding our liability under the TRA.

(5) Represents firm purchase commitments to our suppliers. See Note 6 to the condensed consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information.

Cash distributions for owner tax liabilities are required under the terms of the LLC Operating Agreement. See Note 9 to the condensed consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information regarding tax distributions.

Commencing with the fiscal year ended December 31, 2021, and each fiscal year thereafter, the Credit Agreement requires that we make mandatory prepayments of the Term Loan principal upon certain excess cash flow, subject to certain step-downs based on our first lien net leverage ratio. The mandatory prepayment shall be reduced to 25% or 0% of the calculated excess cash flow if the first lien net leverage ratio was equal to or less than 4.75:1.00 or 4.25:1.00, respectively; however, no prepayment shall be required to the extent excess cash flow calculated for the respective period is equal to or less than $10.0 million. As of June 30, 2024, our first lien net leverage ratio was less than 4.25:1.00.

In connection with our acquisition of Alphazyme, which was completed in January 2023, we were initially required to make contingent payments of up to $75.0 million to the sellers of Alphazyme dependent upon Alphazyme meeting or exceeding defined revenue targets during each of the fiscal years 2023 through 2025. For the first performance period which ended on December 31, 2023, it was determined that the defined revenue target was not achieved. Consequently, no payment for contingent consideration was made to the sellers of Alphazyme in 2024. As of June 30, 2024, we may be required to make contingent payments to the sellers of Alphazyme of up to $45.0 million for the remaining two performance periods. We may also be required to make certain retention payments of $9.3 million to its sellers and certain employees as of various dates but primarily through December 31, 2025 as long as these individuals continue to be employed by the Company. We cannot, at this time, determine when or if the related targets will be achieved or whether the events triggering the commencement of payment obligations will occur. Therefore, such payments were not included in the table above. See Note 3 to the condensed consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional details.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based upon our interim condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosures in the consolidated financial statements. Our estimates are based on historical experience and on various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates under different assumptions or conditions, and any such difference may be material. For a discussion of how these and other factors may affect our business, financial condition or results of operations, see “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023.

The critical accounting estimates that we believe affect our more significant judgments and estimates used in the preparation of our condensed consolidated financial statements presented in this report are described in Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. There have been no material changes to our critical accounting policies or estimates from those set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

Recent Accounting Pronouncements

For a description of the expected impact of recent accounting pronouncements, if any, see Note 1 to the condensed consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.

Market risk

As filed, 3,092 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Interest Rate Risk

As of June 30, 2024, our primary exposure to interest rate risk was associated with our variable rate long-term debt. Borrowings under our Credit Agreement bear interest at a rate equal to the Base Rate plus a margin of 2.00%, with respect to each Base Rate-based loan, or the Term SOFR (Secured Overnight Financing Rate) plus a margin of 3.00% with respect to each Term SOFR-based loan, subject in each case to an applicable Base Rate or Term SOFR floor (see Note 7 to the condensed consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q). Interest rates can fluctuate for a number of reasons, including changes in the fiscal and monetary policies or geopolitical events or changes in general economic conditions. This could adversely affect our cash flows.

As of June 30, 2024, we have an interest rate cap agreement in place to hedge a portion of our variable interest rate risk on our outstanding long-term debt. The agreement has a contract notional amount of $500.0 million and entitles us to receive from the counterparty at each calendar quarter end the amount, if any, by which a specified floating market rate exceeds the cap strike interest rate. The floating interest rate is reset at the end of each three-month period. The contract expires on January 19, 2025.

We had $530.4 million of outstanding borrowings under our Term Loan and no outstanding borrowings under our Revolving Credit Facility as of June 30, 2024. For the three and six months ended June 30, 2024, the effect of a hypothetical 100 basis point increase or decrease in overall interest rates would have changed our interest expense by approximately $1.3 million and $2.7 million, respectively.

We had cash and cash equivalents of $573.2 million as of June 30, 2024. Given the short-term nature of our investments, we do not believe there is any material risk to the value of our investments with increases or decreases in interest rates.

Foreign Currency Risk

All of our revenue is denominated in U.S. dollars. Although approximately 56.0% and 52.3% of our revenue for the three and six months ended June 30, 2024, respectively, was derived from international sales, primarily in Europe and Asia Pacific, all of these sales are denominated in U.S. dollars. The majority of our expenses are generally denominated in the currencies in which they are incurred, which is primarily in the United States. As we endeavor to expand our presence in international markets, to the extent we are required to enter into agreements denominated in a currency other than the U.S. dollar, results of operations and cash flows may increasingly be subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign currency exchange rates. To date, we have not entered into any hedging arrangements with respect to foreign currency risk. As our international operations grow, we will continue to reassess our approach to manage our risk relating to fluctuations in currency rates.

Controls and procedures

As filed, 1,806 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15(e) and 15(d)-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this Quarterly Report on Form 10-Q. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2024.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the three months ended June 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 170 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes to the risk factors disclosed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2024-04-01 to 2024-06-30$73.4mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2024-01-01 to 2024-06-30$137.6mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2024-04-01 to 2024-06-30$38.3mus-gaap:CostOfRevenue
Cost of revenue6 months2024-01-01 to 2024-06-30$76.6mus-gaap:CostOfRevenue
Research and development3 months2024-04-01 to 2024-06-30$5.3mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2024-01-01 to 2024-06-30$10.3mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2024-04-01 to 2024-06-30$40.6mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2024-01-01 to 2024-06-30$81.4mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2024-04-01 to 2024-06-30−$9.5mus-gaap:OperatingIncomeLoss
Operating income6 months2024-01-01 to 2024-06-30−$28.4mus-gaap:OperatingIncomeLoss
Interest expense3 months2024-04-01 to 2024-06-30$11.9mus-gaap:InterestExpense
Interest expense6 months2024-01-01 to 2024-06-30$22.8mus-gaap:InterestExpense
Income tax3 months2024-04-01 to 2024-06-30−$2.4mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2024-01-01 to 2024-06-30−$2.2mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2024-04-01 to 2024-06-30−$7.6mus-gaap:NetIncomeLoss
Net income6 months2024-01-01 to 2024-06-30−$19.7mus-gaap:NetIncomeLoss
Diluted EPS3 months2024-04-01 to 2024-06-30−$0.05us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2024-01-01 to 2024-06-30−$0.15us-gaap:EarningsPerShareDiluted
Basic EPS3 months2024-04-01 to 2024-06-30−$0.05us-gaap:EarningsPerShareBasic
Basic EPS6 months2024-01-01 to 2024-06-30−$0.15us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2024-04-01 to 2024-06-30135,842,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2024-01-01 to 2024-06-30134,088,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2024-01-01 to 2024-06-30$9.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2024-01-01 to 2024-06-30$15.2mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2024-06-30$573.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2024-06-30$685.4mus-gaap:AssetsCurrent
Total assetsAt period end2024-06-30$1.45bnus-gaap:Assets
Current liabilitiesAt period end2024-06-30$68.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2024-06-30$671.2mus-gaap:Liabilities
Long-term debtAt period end2024-06-30$517.1mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2024-06-30$5.4mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2024-06-30$436.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001823239-24-000095. Last ingested by Listed: Nov 13, 2026, 16:14 ET. Listed shows no prices and gives no investment advice.